Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
November 14, 2022
Marc CHALLANDE
Fandifi (FDM.CN) is a tech company focused on building a crowd-based and system-generated prediction & fan engagement platform. The company released on November 10 its Beta Launch is live and can be accessed at www.play.fandifi.com. It is a significant milestone for the company, bringing it closer to its goal of revolutionizing how fans interact with streamed, broadcast, and live events.
You might have witnessed this, and more and more people around you, and probably you, ended up watching media content on non-conventional software and platforms. There is a current switch in the way of watching media, which is reflected in data. According to several surveys, 18-34-year-olds watched 23.4% less live TV in 2020 vs. 2019, and streaming platform viewership has more than doubled in the past three years in contrast, with Western game streaming platforms reaching 8.8 billion hours viewed in Q1 2021, representing an 80% increase YoY. Fandifi gathers many benefits from its experience team to a growing market opportunity. You could first think Fandifi could stop esports, but it aims to expand into every industry with “fans,” meaning movies, music, live events, fashion, food, and more. It is also necessary to mention the company operates an NFT marketplace where rewards can be bought, sold, or traded on an interoperable blockchain-agnostic platform.
“Having developed a fan-centric approach to fan engagement, our team is proud of our work to date and eager to roll out additional tools and features to revolutionize the way that fans interact with streamed, broadcast and live events. Based on the feedback from our community and fans Fandifi will be incorporating their feedback to optimize the content creator and fan experience. It is an exciting time for our team and the company, and we look forward to empowering both organic growth and community engagement.”
David Vinokurov, CEO and President
As mentioned in our introduction, Fandifi has released its new Beta Launch platform, a crowd-based, and system-generated prediction fan engagement platform. Before achieving this, the company had completed its organic beta sign-up campaigns, exceeding initial expectations. Now the forum is open to feedback from its Beta Community. To reach its goals, the company only spent half the budget using psychographic marketing techniques and simple contests to generate impressions and sign-ups. The company also partnered with Elite Duels, a company involved in fantasy sports to Esports. Fandifi is currently targeting the North American and European markets, and players have been able to establish a baseline Cost Per Acquisition (CPA) and are fully confident in moving forward with meaningful efficiencies to lower CPA using previous experiences and lessons learned in the current campaigns and outreach processes.
“We’re excited to activate our partner campaign with Elite Duels, who have built up a solid reputation as a fantasy esports operator over their past several years of operation. Our campaign aims to leverage the tools and resources we have deployed to share our story with highly engaged Esports fans. We’re looking forward to further expanding our partner outreach promotions beyond Elite Duels with additional partners as our marketing program unfolds.”
David Vinokurov, Fandifi CEO and President.
David Vinokurov (CEO) leads Fandifi. David has been an executive with more than 12 years of experience in various industries. Mr. Vinokurov has recently served in management consulting roles for a publicly traded social commerce company, plus several fintech and blockchain-enabled payment companies. He also contributed to raising tens of millions of dollars for start-ups and small-cap companies.
Fandifi is following its game plan. The company first aimed to introduce the solution to consumers in late 2022 with bespoke content and an open platform within gaming. The next step is to bring solutions to businesses across other industries (sports, movies, TV, etc.) and secure pilots and partnerships. The two last steps are the “Enterprise” step (Q1 2023) and the “Growth opportunities & partners” step. The “Enterprise” step will enable predictions for all ages, Esports, and team-based Sports for streaming and broadcast partners. The last step speaks for itself, and the company will aim to find and attract new partners to grow faster and generate more revenue. Fandifi defines its business model in 3 steps: “Crawl, Walk, Run.” The company’s ambitions are clear, but investors are still waiting on the sideline. Fandifi is currently valued at around $7M for a meager stock price of $0.085 (data of November 14). The stock is now just above its 52-week low of $0.065, compared to its 52-week high of $0.255 (April 4, 2022). Investors have complained about the lack of significant revenue for a long time. Given the piece of information shared by Fandifi about its platform, we could expect more substantial income in the short term, meaning the current stock price is resolutely undervalued. To see a better stock price, it will also be crucial for the company to witness its daily volume augmenting. This, combined with better news, could push the company to its fair valuation.
“Crawl, Walk, Run.” This quote defines well the company’s ambitions. Fandifi (FMD.CN) is involved in a fast-expanding market and doesn’t just settle for esports and sports markets but for all sectors with fans. Given the current valuation, Fandifi flies under the radar, and any news with strategic partnerships will help Fandifi to reach new highs.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts